Morvan A, Gazon M, Duperret S, Schmitt Z, Pradat P, Mohkam K, Aubrun F
Department of Anesthesiology and Critical Care Croix-Rousse University Hospital, Hospices Civils de Lyon (HCL), Lyon, France.
Department of Hepatology, Clinical Research Center Croix-Rousse University Hospital, Hospices Civils de Lyon (HCL), Lyon, France.
Int J Organ Transplant Med. 2020;11(4):166-175.
Although liver transplantation (LT) improves survival in cirrhotic patients with hepatopulmonary syndrome (HPS), few data exist concerning post-operative complications in these patients.
To compare complications after LT between patients with and without HPS.
In a case-control study, we retrospectively analyzed all patients who underwent LT in our center from January 2010 to July 2016. We compared cases of identified HPS to controls matched for age, MELD score, comorbidities, red blood cells transfused, and highest dosage of norepinephrine perfused during transplantation.
Among 451 transplanted patients, we identified 71 patients with HPS who could be analyzed. We found a significantly (p<0.001) higher number of post-operative complications in patients with HPS (median 5 3), with more occurrence of cardiac, infectious and surgical complications than in the controls: 39.4% 12.7% (p<0.001), 81.7% 49.3% (p<0.001), and 59.2% 40.1% (p<0.029), respectively. There were also more ICU readmissions at 1 month among HPS patients (10 1, p=0.01). There was no significant difference concerning ventilation data, lengths of ICU or hospital stay (8.5 [range 3-232] and 32 [14-276] days, respectively on the whole cohort) and death in the ICU (4.2% on the whole cohort). The 1-year survival was higher in HPS patients (94.4% 81.1%, p=0.034); there was no difference in 5-year survival.
HPS patients seem to have a higher number of complications in the first month following LT.
尽管肝移植(LT)可提高肝硬化合并肝肺综合征(HPS)患者的生存率,但关于这些患者术后并发症的数据很少。
比较肝移植术后有和没有HPS患者的并发症情况。
在一项病例对照研究中,我们回顾性分析了2010年1月至2016年7月在本中心接受肝移植的所有患者。我们将确诊为HPS的病例与年龄、终末期肝病模型(MELD)评分、合并症、输注红细胞量以及移植期间去甲肾上腺素最高灌注剂量相匹配的对照组进行比较。
在451例移植患者中,我们确定了71例可分析的HPS患者。我们发现HPS患者术后并发症数量显著更多(p<0.001)(中位数为5对3),与对照组相比,心脏、感染和手术并发症的发生率更高:分别为39.4%对12.7%(p<0.001)、81.7%对49.3%(p<0.001)和59.2%对40.1%(p<0.029)。HPS患者在1个月时再次入住重症监护病房(ICU)的情况也更多(10对1,p=0.01)。在通气数据、ICU住院时间或住院时间(整个队列分别为8.5天[范围3 - 232天]和32天[14 - 276天])以及ICU死亡率(整个队列的4.2%)方面没有显著差异。HPS患者1年生存率更高(94.4%对81.1%,p=0.034);5年生存率没有差异。
HPS患者在肝移植后的第一个月似乎有更多并发症。